Dottikon ES Holding AG

DESN

CH0582581713

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 07:20:01 2024-04-25 am EDT			5-day change	1st Jan Change
229.5 ^CHF	-1.50%		+4.51%	+1.09%

2023	Dottikon ES Posts Lower Fiscal H1 Net Income; Sales Up	MT
2023	Dottikon ES Holding AG Reports Earnings Results for the Half Year Ended September 30, 2023	CI

Dottikon ES : Presentation of the Full-Year Results as of March 31, 2015

May 28, 2015 at 11:30 am EDT

The Full-Year results for the business year 2014/15 of DOTTIKON ES Group will be published on May 29, 2015.

distributed by

Latest news about Dottikon ES Holding AG

Dottikon ES Posts Lower Fiscal H1 Net Income; Sales Up	Nov. 28	MT
Dottikon ES Holding AG Reports Earnings Results for the Half Year Ended September 30, 2023	Nov. 27	CI
Dottikon ES Free Float Rises Amid Share Sale by Majority Investor	23-06-16	MT
Dottikon ES' Majority Shareholder Kicks Off Share Sale	23-06-14	MT
Dottikon ES Holding AG: Under the radar	23-06-02
Dottikon ES Holding AG Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-31	CI
Dottikon ES Posts Higher FY23 Net Income; Net Sales Rise	23-05-31	MT
Dottikon Es Holding AG Reports Earnings Results for the Half Year Ended September 30, 2022	22-11-29	CI
Swiss Chemicals Group Dottikon's Fiscal H1 Profit Jumps On Revaluation Of Deferred Tax Liabilities	22-11-29	MT
Switzerland's Dottikon Forecasts Higher FY23 Sales Amid 31% Growth in Fiscal H1	22-10-21	MT
Swiss Chemicals Group Dottikon Unveils Additional Measures To Cut Energy Consumption	22-10-13	MT
Global markets live: Credit Suisse, Telecom Italia, GSK, Apple, Boeing...	22-05-31
Dottikon Es Holding AG Reports Earnings Results for the Full Year Ended March 31, 2022	22-05-31	CI
Swiss Chemicals Group Dottikon's FY22 Profit Climbs 13% As Net Sales, Order Volume Grow	22-05-31	MT
Certain Shares of Dottikon Es Holding AG are subject to a Lock-Up Agreement Ending on 14-DEC-2021.	21-12-13	CI
Dottikon Es Holding AG Reports Earnings Results for the Half Year Ended September 30, 2021	21-11-26	CI
Dottikon ES Fiscal H1 Profit Rises 13% as Sales Grow	21-11-26	MT
Dottikon Es Holding AG(SWX:DESN) added to S&P Global BMI Index	21-09-20	CI
Dottikon Es Holding AG(SWX:DESN) added to Swiss Performance Index (Price Return)	21-06-28	CI
Dottikon Es Holding Ag Reports Earnings Results for the Full Year Ended March 31, 2021	21-05-28	CI
Dottikon ES : Raises $214 Million Via Share Offering	21-03-10	MT
Dottikon ES : Books Fully Covered in Share Offering	21-03-08	MT
Dottikon ES : Core Shareholders Exercise Pre-Emptive Rights in Share Offering	21-03-05	MT
Dottikon ES : Plans $244 Million Capital Raise to Finance Expansion	21-02-26	MT
Dottikon ES Plans Capital Increase	21-02-18	CI

Dottikon ES Holding AG is a Switzerland-based holding company that specializes in hazardous chemistry and focuses on the exclusive synthesis of fine chemicals for the pharmaceutical and chemical industries. Its product range includes active pharmaceutical ingredients (APIs) and pharmaceutical intermediates, as well as industrial chemicals. Its pharmaceutical products can be found in medications for, among others, heart disease, asthma, high blood pressure and ulcers. Dottikon ES Holding AG's industrial end products include food additives, cosmetics, electro-chemicals, photo-chemicals and agricultural chemicals. The Company also offers distillation plants and thin layer evaporators for the recycling of solvents, as well as high temperature incinerators for the waste treatment of hazardous waste. As of March 31, 2012, the Company had two wholly owned subsidiaries: DOTTIKON EXCLUSIVE SYNTHESIS AG and DOTTIKON ES MANAGEMENT AG. It also held a 33.9%-stake in SYSTAG, System Technik AG.

Sector

Pharmaceuticals

Calendar

2024-05-27 - Q4 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Dottikon ES Holding AG: Under the radar

June 02, 2023 at 04:22 am EDT

More Strategies

Ratings for Dottikon ES Holding AG

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

233

Average target price

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
DOTTIKON ES HOLDING AG	+1.09%	3.51B
ELI LILLY AND COMPANY	+25.61%	660B
NOVO NORDISK A/S	+22.70%	562B
JOHNSON & JOHNSON	-5.24%	358B
MERCK & CO., INC.	+16.49%	322B
ABBVIE INC.	+8.28%	297B
ASTRAZENECA PLC	+12.74%	219B
ROCHE HOLDING AG	-9.78%	196B
NOVARTIS AG	+6.61%	199B
PFIZER, INC.	-8.75%	149B

Other Pharmaceuticals

Dottikon ES Holding AG

Equities

DESN

CH0582581713

Pharmaceuticals

Dottikon ES : Presentation of the Full-Year Results as of March 31, 2015

Latest news about Dottikon ES Holding AG

Chart Dottikon ES Holding AG

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Dottikon ES Holding AG

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Other Pharmaceuticals